Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
Get Alerts DBTX Hot Sheet
Join SI Premium – FREE
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET.
A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.
Investor Contact:Julie SeidelStern Investor Relations, Inc.[email protected]212-362-1200
Media Contact:Chris RaileyTen Bridge Communications[email protected]617-834-0936
Source: Decibel Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corner Table Restaurants Brings Together The Smith and Parla in 17,000-Square-Feet on West 41st Street, Anchoring 42BELOW’s Burgeoning Food Scene
- AM Best Affirms Credit Ratings of AVLA Re Ltd.
- BTC Price Reclaims $81K as Fed Comments Lift Crypto, While Apeing Nears September 8 Launch as Best Crypto in 2026 Contender
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share